Across TCGA pan-cancer cohorts, C18orf63 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated C18orf63 data layer compared with 16 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher C18orf63 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated C18orf63 expression acts as an unfavorable survival marker.

UCEC and CHOL are the cancer types where C18orf63 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: C18orf63 tumor-vs-normal RNA expression · all C18orf63 data types